Core Viewpoint - Fangsheng Pharmaceutical's subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of its generic drug, RuLuGoli Tablets [1] Group 1 - The approval is a significant milestone for the company's drug development efforts [1] - The clinical trial approval indicates progress in the company's research and development pipeline [1]

证券日报网讯 10月15日晚间，方盛制药发布公告称，公司控股股东暨实际控制人张庆华先生办理完成 了3，500万股股份质押手续。 （文章来源：证券日报） ...

Group 1 - High Energy Environment reported a net profit of 646 million yuan for the first three quarters, a year-on-year increase of 15.18% [1] - Tianzhun Technology received approval from the China Securities Regulatory Commission for issuing convertible bonds to unspecified objects [1] - Energy Conservation Wind Power achieved a cumulative power generation of 9.349 billion kWh, a year-on-year increase of 1.72% [1][2] Group 2 - Sichuan Road and Bridge's total amount of projects won in the first three quarters reached 97.173 billion yuan, a year-on-year increase of 25.16% [3] - Shaanxi Energy's power generation in the third quarter decreased by 1% year-on-year, while its coal sales increased by 136.98% [3][4] Group 3 - Jintuo Co. announced that four shareholders plan to reduce their holdings by up to 2.95% of the company's shares [5] - Tailin Microelectronics expects a net profit increase of 118% year-on-year for the first three quarters, with revenue of approximately 766 million yuan [6] - Asia-Pacific Co. anticipates a net profit of 310 million to 335 million yuan for the first three quarters, a year-on-year increase of 97.38% to 113.30% [8] Group 4 - He Sheng New Materials expects a net profit increase of 60% to 80% for the first three quarters, with a projected profit of 137 million to 154 million yuan [9] - Spring Airlines reported a passenger turnover of 4.835 billion person-kilometers in September, a year-on-year increase of 22.87% [10][11] Group 5 - Mingxin Xuteng received a notification from a leading new energy vehicle company for a project worth approximately 650 million yuan [12] - Acolyte's subsidiary received a government subsidy of 47.13 million yuan for fixed asset investment [13] Group 6 - Fangsheng Pharmaceutical's subsidiary received approval for clinical trials of a new drug for treating advanced prostate cancer [14] - Aofu Technology plans to sell idle factory assets for a total price of 23.852 million yuan [16] Group 7 - Ganyue Expressway reported a service income of 313 million yuan in September [18] - Dong'an Power secured five new market agreements in the third quarter, with a total projected sales volume of approximately 1 million units [20] Group 8 - Zhongmin Energy achieved a cumulative power generation of 1.922 billion kWh, a year-on-year increase of 1.25% [21] - Pan-Asia Micro-Pore's application for issuing shares to specific objects has been accepted by the Shanghai Stock Exchange [23] Group 9 - Shenghui Integration reported an order balance of 2.214 billion yuan as of September 30, a year-on-year increase of 21.21% [24] - Jineng Technology's vice president resigned for personal reasons [25] Group 10 - Ruixin Microelectronics expects a net profit increase of 116% to 127% for the first three quarters, with a projected profit of 760 million to 800 million yuan [33] - Shanghai Pharmaceuticals received FDA approval for a new drug application for doxycycline capsules [34] Group 11 - Ruima Precision's subsidiary received a project notification for air suspension systems from a domestic automaker, with a total sales forecast of approximately 265 million yuan [36] - Galaxy Magnetics anticipates some impact on its export business due to the Ministry of Commerce's announcement on export controls for certain rare earth items [37] Group 12 - Ba Tian Co. expects a net profit increase of 230.79% to 260.15% for the first three quarters, with a projected profit of 676 million to 736 million yuan [43] - Donglai Technology plans to reduce its repurchased shares by up to 1% of the total share capital [45] Group 13 - Guangkang Biochemical announced that shareholders plan to reduce their holdings by up to 2.68% of the company's shares [46] - Nanwang Energy reported a net profit increase of 37.13% for the first three quarters, with a total revenue of 5.32 billion yuan [48] Group 14 - Yahua Group expects a net profit increase of 106.97% to 132.84% for the first three quarters, with a projected profit of 320 million to 360 million yuan [49] - Hualitai's annual production project for 20,000 tons of benzidine has been successfully completed and is now in full production [51]

Group 1 - The company Fangsheng Pharmaceutical announced that its controlling shareholder Zhang Qinghua has completed the pledge of 35 million shares as of October 15, 2025 [1] - Zhang Qinghua directly holds approximately 156 million shares, accounting for 35.53% of the total shares (approximately 439 million) [1] - The total number of pledged shares by Zhang Qinghua is approximately 101 million, which represents 64.67% of his directly held shares and 22.98% of the company's total shares [1] Group 2 - The subsidiary of Hunan Kaishun Investment Consulting Co., Ltd., controlled by Zhang Qinghua, holds about 9.13 million shares, with no shares pledged [1] - Zhang Zhurong holds approximately 420,000 shares, with no shares pledged [1] - In total, Zhang Qinghua and his concerted parties hold about 166 million shares, with approximately 101 million shares pledged, representing 60.94% of their total holdings [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received the clinical trial approval notice from the National Medical Products Administration for the development of the generic drug RuLuGoli tablets, which will be used for clinical trials in prostate cancer [1] Group 1 - The approval allows Fangsheng Jianmeng to proceed with clinical trials for RuLuGoli tablets [1] - The drug is aimed at treating prostate cancer, indicating a strategic focus on oncology within the company's product pipeline [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "Fangsheng Jianmeng"), has received approval from the National Medical Products Administration for the clinical trial of its generic drug, RuLuGuoLi tablets, for the treatment of prostate cancer [1] Group 1 - The clinical trial approval indicates a significant step forward in the development of RuLuGuoLi tablets [1] - The project is part of the company's strategy to expand its product offerings in the oncology sector [1]

Group 1 - Company announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received the clinical trial approval notice from the National Medical Products Administration for the development of the generic drug RuLuGuoLi tablets [1] - This approval marks a significant step in the company's efforts to expand its pharmaceutical product offerings and enhance its research and development capabilities [1]

证券代码：603998 证券简称：方盛制药 公告编号：2025-084 湖南方盛制药股份有限公司 关于子公司获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，湖南方盛制药股份有限公司（以下简称"公司"或"方 盛制药"）全资子公司广东方盛健盟药业有限公司（以下简称"方 盛健盟"）化药仿制药研发项目瑞卢戈利片收到国家药品监督管 理局核准签发的《药物临床试验批准通知书》。现将相关情况公 告如下： 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 一、药物的基本情况 药物名称：瑞卢戈利片 剂型：片剂 注册分类：化药 3 类 申请事项：临床试验 受理号：CYHL2500136 审批结论：根据《中华人民共和国药品管理法》及有关规定， 经审查，2025 年 8 月 1 日受理的瑞卢戈利片临床试验申请符合 药品注册的有关要求，同意本品开展前列腺癌的临床试验。 二、药品的相关情况 瑞卢戈利片为一种促性腺激素释放激素（GnRH）受体拮抗 剂，用于治疗成人 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●湖南方盛制药股份有限公司（以下简称"公司"）控股股东暨实际控制人张庆华 先生办理完成了3,500万股（占公司总股本的7.97%）股份质押手续； ●截至本公告披露日，张庆华先生直接持有公司的股份总数为156,019,500股，占公 司股份总数（439,081,360股）的35.53%；张庆华先生质押的公司股份总数为100,905,200 股（含本次增加质押的股份），占其直接持有公司股份总数的64.67%，占公司股份总数 的22.98%；张庆华先生控股的湖南开舜投资咨询有限公司之控股子公司泰州共生咨询有 限公司（原"泰州共生创业投资管理有限公司"，以下简称"共生咨询"）持有公司股 份数为9,131,807股，共生咨询质押的公司股份总数为0股；张祖嵘女士持有公司股份数 423,300股，张祖嵘女士质押的公司 ...

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration for the development of the generic drug RuLuGoli Tablets, which is a GnRH receptor antagonist for the treatment of advanced prostate cancer in adults [1] Company Summary - The RuLuGoli Tablets have not yet been launched in China, and there are currently no original or generic products approved for sale in the country [1] - Other companies, such as Haibu Pharmaceutical and Lianhuan Pharmaceutical (600513), have also received clinical trial approvals and plan to conduct related clinical trials [1]